LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

32.2 -3.3

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

31.96

Massimo

33.24

Metriche Chiave

By Trading Economics

Entrata

23M

28M

Vendite

20M

141M

P/E

Media del settore

12.163

77.256

Margine di Profitto

19.97

Dipendenti

370

EBITDA

25M

38M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+35.3% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

786M

5.3B

Apertura precedente

35.5

Chiusura precedente

32.2

Notizie sul Sentiment di mercato

By Acuity

34%

66%

114 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 nov 2025, 21:06 UTC

I principali Market Mover

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7 nov 2025, 22:36 UTC

Utili

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Utili

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Utili

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Utili

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Discorsi di Mercato

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Utili

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Discorsi di Mercato

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Discorsi di Mercato

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Utili

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Utili

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Discorsi di Mercato

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Discorsi di Mercato

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

7 nov 2025, 17:17 UTC

Acquisizioni, Fusioni, Takeovers

Satair Expects to Complete Purchase in Early 2026

7 nov 2025, 17:17 UTC

Acquisizioni, Fusioni, Takeovers

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7 nov 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7 nov 2025, 17:09 UTC

Discorsi di Mercato

PENN Is Falling Further Behind Competitors -- Market Talk

7 nov 2025, 16:49 UTC

Discorsi di Mercato

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7 nov 2025, 16:24 UTC

Discorsi di Mercato

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7 nov 2025, 16:17 UTC

Discorsi di Mercato

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

35.3% in crescita

Previsioni per 12 mesi

Media 45 USD  35.3%

Alto 60 USD

Basso 11 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

4

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

114 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat